Drug Trial Radar · NCT07380113
Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jun 22, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Zhujiang HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare a new intravenous drug, Anruikefen, with a traditional oral medication, nalfurafine orally disintegrating tablets, in improving sleep quality in patients with chronic kidney disease-associated pruritus. Sleep quality will be primarily assessed using the Pittsburgh Sleep Quality Index (PSQI). The study will also evaluate the safety of Anruikefen. The main questions it aims to answer are: * Does Anruikefen injection improve sleep quality better than oral nalfurafine? * Does Anruikefen injection improve patients' quality of life more than oral nalfurafine? Researchers will compare Anruikefen with nalfurafine (an active control drug) to evaluate differences in their effects on sleep quality in patients with chronic kidney disease-associated pruritus. Participants will: * Receive either Anruikefen injection (0.3 μg/kg, three times per week) or nalfurafine hydrochloride orally disintegrating tablets (2.5 μg once daily). * Continue treatment for 4 weeks, followed by a 1-week safety follow-up. * Complete the Pittsburgh Sleep Quality Index and other quality-of-life questionnaires after one month.
Conditions
- Pruritus Chronic
- Kidney Diseases, Chronic
- Renal Insufficiency, Chronic
- Uremia; Chronic
- Pruritus Due to Systemic Disorder (Disorder)
- Pruritus Due to Hemodialysis
Interventions
AnrikefonDrug
intravenous administration
NalfurafineDrug
oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pittsburgh Sleep Quality IndexTime frame: Baseline, 4 weeks after medication
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhujiang Hospital, Southern Medical University, No. 253 Gongye Road, Guangzhou, 510282, China
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.